The United Kingdom and the United States have reached a major commercial pact that will ensure zero tariffs on British medicine shipments entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these crucial products will be held at nothing for a duration of 36 months.
This development follows previous warnings to hike duties on patented drug products, with figures mentioned reaching 100%.
"This deal with the Britain reinforces the global environment for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," a release said.
Trade Significance
Pharmaceuticals are one of the UK's most significant export categories to the US, which is by far the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This amount made up a significant portion of all goods exports in that timeframe.
"This deal safeguards work, increases funding and facilitates the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key NHS Changes
The deal involves several key pledges from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double total NHS spending on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must pay back to the NHS to stay within budget will be limited at 15%. Previously, repayments exceeded twenty percent.
Recent Tensions
This agreement follows a ongoing tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were exacerbated by arguments that US customers were charged significantly more for the identical medicines than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been paused or cancelled, while major investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
